ReviewFrontiers in oncology2026
The pathological landscape of tumor evolution: a paradigm shift from morphology to functional networks.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor pathology is undergoing a profound transformation, shifting from pure morphological description toward multidimensional functional network analysis. This Mini Review focuses on the tumor microenvironment (TME) as a central concept driving tumor initiation, progression, and therapeutic resistance. We first outline the limitations of traditional pathological classification and elaborate on how the dynamic co-evolution of cellular components (such as cancer-associated fibroblasts (CAFs) and immune cells) along with the extracellular matrix (ECM) constitutes a functional unit. Key controversies are discussed, including the translational hurdles of TME-directed therapies and the challenge of spatiotemporally assessing tumor heterogeneity. We further identify critical research gaps, particularly the mechanistic understanding of the tumor-host interface across scales. Finally, we envision that the integration of artificial intelligence-driven spatial pathology, single-cell multi-omics, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.